<div id="readability-page-1"><p>In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Revolution Medicines, with a price target of <span id="expert-recommendation-target">$200.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Kasimov is a 5-star analyst with an average return of <span>16.5%</span> and a 56.85% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Summit Therapeutics, and Vertex Pharmaceuticals.</p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $176.95 average price target.</p></div>

RVMD

SBIO

LABU

<p>Evercore ISI analyst Cory Kasimov has reaffirmed a Buy rating for Revolution Medicines (RVMD) with a price target of $200.00. Kasimov, a 5-star analyst, has an average return of 16.5% and a success rate of 56.85%. The overall analyst consensus for Revolution Medicines is a Strong Buy, with an average price target of $176.95.</p>

Tip Ranks

Revolution Medicines

SPDR S&P Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Evercore

Summit Therapeutics

Vertex Pharma

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

Evercore ISI Sticks to Their Buy Rating for Revolution Medicines (RVMD)